Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer.

Current cancer drug targets - 1 Mar 2007

Nakao A, Takeda S, Shimoyama S, Kasuya H, Kimata H, Teshigahara O, Sawaki M, Kikumori T, Kodera Y, Nagasaka T, Goshima F, Nishiyama Y, Imai T

Abstract excerpt

We reviewed our clinical trial using mutant herpes simplex virus "HF10". We have evaluated the safety and effect of HF10 against recurrent breast cancer since 2003 and also applied HF10 to non-resectable pancreatic cancer since 2005. An oncolytic herpes simplex virus type 1, mutant HF10, has been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Breast Neoplasms
Share to Herpesvirus 1, Human

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oncolytic Virotherapy

Share to Pancreatic Neoplasms

Share to Research Design

Share to Treatment Outcome

Share to Virus Replication

Source

Identifiers

PMID: 17346108
DOI: 10.2174/156800907780058808

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17346108-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer.PMID 17346108Read ↗

[Novel treatment with oncolytic herpes simplex virus, 'HF10' against breast cancer].Semantic proximity Read ↗

Phase I Dose-escalation Clinical Trial of HF10 Oncolytic Herpes Virus in 17 Japanese Patients with Advanced Cancer.Semantic proximity Read ↗

A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.Semantic proximity Read ↗

Intraperitoneal oncolytic and tumor vaccination therapy with replication-competent recombinant virus: the herpes paradigm.Semantic proximity Read ↗

Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer.Semantic proximity Read ↗

Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy.Semantic proximity Read ↗

Feasibility of herpes simplex virus type 1 mutants labeled with radionuclides for tumor treatment.Semantic proximity Read ↗

Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus.Semantic proximity Read ↗

The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma.Semantic proximity Read ↗

Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice.Semantic proximity Read ↗

Improved oncolytic activity of a reovirus mutant that displays enhanced virus spread due to reduced cell attachmentSemantic proximity Read ↗

[Progess on research of herpes simplex virus type 1 mutants for cancer therapy].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.